Media Coverage

To explore what the next year may hold, MLO spoke with 12 laboratory professionals whose roles span bench operations, laboratory quality, enterprise leadership, diagnostics innovation, and health-tech entrepreneurship. Their predictions reflect both optimism and urgency: calls to rebuild the workforce pipeline, integrate multi-site networks, strengthen clinical collaboration, modernize infrastructure, and streamline the process of test result to clinical action. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics: "Laboratories across the United States will need to continue being agile and flexible to meet demands from patients, providers, and health systems. That is particularly true in areas like preventive health and wellness, where growth of alternative, consumer-driven models of care will force traditional healthcare providers to be more innovative, dynamic, and user-friendly, allowing patients to interact with this new and growing system closer to home through lab networks like Quest Diagnostics."

Only approximately one-third of US adults diagnosed with hepatitis C virus (HCV) infection received treatment from 2014 to 2021, despite the widespread availability of curative therapies, according to study results published in the Journal of Viral Hepatitis. The US has the fifth highest burden of HCV worldwide. The World Health Organization (WHO) set a goal to eliminate HCV in 2030 by diagnosing at least 90% and treating at least 80% of individuals infected with HCV. Investigators analyzed deidentified data from 2 large commercial laboratories: LabCorp and Quest Diagnostics.

Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care. By D. Alagia III, MD, MS, MBA, FACS, FACOG, Quest Diagnostics

Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid recurrence, while others are already cured. Determining who falls into each group remains a major challenge in cancer care. “One of the challenges facing ctDNA technologies is, how do we identify ctDNA molecules that are very low abundance in circulation with high accuracy?” said Dan Edelstein, the vice president and general manager of Haystack Oncology at Quest Diagnostics®. Recognizing the need to detect ctDNA reliably, Haystack Oncology developed Haystack MRD®, a next-generation workflow for ultrasensitive residual disease monitoring.

Social media is flooded with ads for at-home blood testing services that promise insights into healthier living, so ABC News' Becky Worley tried one to see what the results really reveal. Becky recieved her blood draw at Quest's patient service center in Oakland, California.

A cancer treatment laboratory in Lewisville made a medical breakthrough that could decrease the risk of the disease returning after a patient has been treated. After somebody has been treated for a cancerous tumor, very small amounts of disease may remain in the body, which traditional tests may miss. Quest Diagnostics, headquartered in Lewisville, has created a new blood test that can identify tiny bits of cancer post-treatment. Currently, Lewisville’s Quest Diagnostics laboratory is the only lab in the country that processes this test for patients and doctors nationwide.

Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.

During a talk at the Jefferies Healthcare Services Conference this week, Quest Diagnostics CFO Sam Samad noted developments within several parts of the company's advanced testing business and highlighted blood-based Alzheimer's testing as a particularly strong growth area.

Guardant Health and Quest Diagnostics will collaborate to offer Guardant’s Shield blood-based colorectal cancer test through Quest’s distribution network, the companies said Wednesday. Physicians will be able to order the test through their Quest accounts and electronic health record starting in the first quarter of 2026.

Overall rates of HIV drug resistance declined by nearly 17% between 2018 and 2024, according to a large analysis from Quest Diagnostics published in Open Forum Infectious Diseases. The researchers assessed the prevalence of mutations that confer resistance to nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors.

Quest Diagnostics has struck a deal to use healthcare software firm Epic Systems' suite of enterprise laboratory software and services, the companies said on Tuesday. Under the agreement, Epic's enterprise offerings — including its Aura specialty lab data exchange system, its Beaker lab information system, and its MyChart patient health record portal — will be implemented across Quest's national lab operations.

The collaboration will allow wearable device users to order clinical tests, schedule appointments, and receive results through the WHOOP mobile application. WHOOP announced that Quest Diagnostics will serve as the US lab provider for WHOOP Advanced Labs, a new feature that will integrate clinical laboratory testing into the wearable device company’s mobile application.

Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.

The relationship between Quest Diagnostics and Hackensack Meridian Health is taking another test. For the last four years, the Secaucus-based lab services provider has managed laboratory operations and performed reference testing for 11 hospitals in the Edison-headquartered health care network. Quest recently deepened that collaboration by opening its 250,000-square-foot next-generation flagship laboratory in Clifton to give students at Hackensack Meridian Health’s School of Medicine a behind-the-scenes look at clinical lab work.

Quest Diagnostics has launched a pharmacogenomic (PGx) laboratory test service designed to help healthcare providers understand individual genetic responses to select drug therapies and optimize medication selection and dosing decisions.

New research by Quest Diagnostics suggests that more and more U.S. workers are using the powerful synthetic opioid drug fentanyl, since it’s showing up in random drug tests carried out in workplaces across the country. This bleak news might not be too surprising, given the dramatic speed with which the drug has affected a population that remains plagued by opioid addiction.

Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications. This service is intended to support clinicians in selecting appropriate drugs and determining optimal dosages.

More Americans are testing positive for fentanyl use in randomized workplace drug tests, highlighting a persistent challenge for employers. The positive rate for urine tests indicating the presence of the synthetic opioid fentanyl was 1.13% in 2024. That is up from 0.91% in 2023 and double the rate in 2020, according to a recent analysis of more than eight million drug tests by Quest Diagnostics, one of the U.S.’s largest drug-testing labs.

Jeff Lusby is the general manager of healthcare IT solutions at Quest Diagnostics. With more than 29 years in healthcare IT, Lusby has extensive experience with technology implementations, from the sales journey to installation, support and account management. In his current role, he leads Quest’s Quanum Enterprise Content Solutions software business.

Corewell Health has signed on to a joint venture with Quest Diagnostics covering inpatient and outpatient lab management and the construction of a new 100,000-square-foot advanced lab facility.

Independent laboratory company Quest Diagnostics and Corewell Health entered a definitive agreement to build a jointly owned lab in Michigan. The Diagnostic Lab of Michigan would be based at the Corewell Health Southfield Center in Southfield, Michigan. It would focus on automated microbiology and high-throughput molecular testing.

Quest Diagnostics said on Monday the US Food and Drug Administration has granted breakthrough device designation for the firm's Haystack minimal residual disease (MRD) test. The tumor-informed, whole-exome sequencing assay detects circulating tumor DNA in blood to identify MRD-positive patients with stage II colorectal cancer who have received curative-intent surgical treatment and may benefit from adjuvant therapy. Quest acquired the test when it bought Haystack Oncology in 2023.

Quest Diagnostics, a provider of diagnostic information services, has been scaling its efforts in the digital pathology space through an ongoing collaboration with PathAI. “Beyond assisting the pathologist in looking at and identifying problem areas on the slide, there are a lot of AI tools that can help the pathologist become more efficient and work more quickly,” said Chad Richards, president of pathology and medical services at Quest Diagnostics.

Quest Diagnostics has completed its acquisition of some clinical testing assets from Spectra Laboratories, a subsidiary of dialysis company Fresenius Medical Care.

During Quest Diagnostics' most recent investor day presentation, President and CEO Jim Davis highlighted the sale of data and data analytics as among the fastest growing businesses within the company. As at Tricore, part of this effort is focused not only on identifying but closing patient care gaps, said David Freeman, VP and general manager of healthcare analytics solutions at the company. Using data generated by a lab, "A health plan can create a standing order for a lab test for a particular patient based on closing a gap in care," he said. If the patient then shows up at a Quest location for another service, "and that standing order exists, we can add that test and close that gap," he said.